Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease

Plain-language summary

This study examines an allogeneic (donor-derived) Anti-CD19 CAR-T cell therapy in patients with refractory Graves' disease, an autoimmune condition affecting the thyroid gland. Patients whose disease does not respond to standard treatment and who meet specific laboratory criteria may take part. The study is being conducted in Early Phase 1 and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Early Phase 1

Status

Recruiting

Sponsor

Shanghai Zhongshan Hospital

Intervention

Allogeneic CAR-T

Start date

8/10/2025

Estimated completion

3/31/2027

Countries

China

Related genes

Locations

• Shanghai, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Subjects with refractory Graves disease, which is defined as meeting any one of the following criteria: a. Failure to discontinue medication after continuous standard antithyroid therapy for ≥ 3 years; b. Hyperthyroid state requiring medication after receiving ≥ 2 times of radioiodine therapy (with the last dose of radioiodine administered at least 6 months prior); c. Relapse ≥ 2 times after cessation of medication upon meeting the criteria for treatment discontinuation.
* Serum TRAb ≥ 3 times greater than normal range (≥ 5 IU/L)
* Positive expression of CD19 on peripheral blood B cells determined by flow cytometry.
* Participation in this clinical study is willing to sign an informed consent with good compliance with treatment and follow-up.

(Criteria for treatment discontinuation is define as receiving continuous anti-thyroid drug therapy for ≥18 months, and maintaining euthyroid status for ≥6 months, plus negative TRAb and TSI. Relapse is defined as recurrence of hyperthyroidism and positive TRAb/TSI after meeting the criteria for treatment discontinuation and stopping medication.)

Exclusion Criteria:

* History of severe drug allergies or allergic constitution;
* Presence or suspicion of uncontrolled infections requiring intravenous treatment (fungal, bacterial, viral or other);
* Presence of central nervous system disorders (including epilepsy, psychosis, cerebrovascular accident, encephalitis, CNS vasculitis, etc);
* Presence of clinically significant heart diseases (e.g., angina pectoris, myocardial infarction, heart failure, severe arrhythmias, etc);
* Subjects with congenital immunoglobulin deficiency;
* Patients with malignant tumors;
* Subjects who are: 1. HBsAg or HBcAb positive with detectable peripheral blood HBV DNA; 2. HCV antibody positive with detectable HCV RNA; 3. Positive HIV antibody; 4. Syphilis test positive;
* Subjects with psychiatric disorders or severe cognitive dysfunction;
* Hematopoietic function: a. White blood cell count \< 3.5×10\^9/L b. Neutrophil count \< 1.5 x 10\^9/L; c. Hemoglobin \< 110g/L.
* Liver function: ALT\> 3×ULN, AST \> 3×ULN, TBIL \> 2.5×ULN.
* Renal function: creatinine clearance rate (CrCl) \< 60 ml/minute (calculated based on Cockcroft/Fault formula).
* Cardiac function: LVEF \< 55%
* Coagulation function: International standardized ratio (INR) ≥ 1.5×ULN, prothrombin time(PT) \>1.5 × ULN.
* Participation in other clinical trials within 3 months prior to enrollment;
* Pregnancy or planning pregnancy;
* Other conditions considered by investigators as unsuitable for participation.